Ovary

GLORIOSA

GLORIOSA is a Phase 3 multicenter, open label study designed to evaluate the safety and efficacy of Mirvetuximab Soravtansine in participants with platinum-sensitive ovarian, primary peritoneal or fallopian tube cancers with high folate receptor-alpha (FRα) expression.

IMGN853-0424

A Randomized Phase 2 Study of Ocular Toxicity Evaluation and Mitigation During Treatment with Mirvetuximab Soravtansine in Patients with Recurrent platinum-resistant or platinum-sensitive Ovarian Cancer with High Folate Receptor-Alpha Expression. 

GOG 3087 NXP800

A Phase 1b Clinical Study of NXP800 in Subjects With Ovarian Cancer. NXP800 is administered to patients with platinum-resistant, ARID1a-mutated ovarian carcinoma. NXP800 is an anti-neoplastic, oral small molecule.

NRG-GY019

This phase III trial studies how well letrozole with or without paclitaxel and carboplatin works in treating patients with stage II-IV low-grade serous carcinoma of the ovary, fallopian tube, or peritoneum. Letrozole is an enzyme inhibitor that lowers the amount of estrogen made by the body which in turn may stop the growth of tumor cells that need estrogen to grow.

PRESERVE-004

Phase 2 Randomized Open-label Multicenter Study of Combination of ONC-392 and Pembrolizumab for the Treatment of patients with Platinum Resistant Ovarian Cancer (PROC).ONC-392 is a next-generation anti-CTLA-4 monoclonal antibody.

Uterine/Endometrial

XPORT-EC

A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of
Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-
Type, Advanced or Recurrent Endometrial Carcinoma

NRG-GY026

This phase II/III trial tests whether adding trastuzumab and hyaluronidase-oysk (Herceptin HylectaTM) or pertuzumab, trastuzumab and hyaluronidase-zzxf (PhesgoTM) to the usual chemotherapy (paclitaxel and carboplatin) works to shrink tumors in patients with HER2 positive endometrial serous carcinoma or carcinosarcoma. 

Surgical

NRG-CC008 

This trial studies how well two surgical procedures (bilateral salpingectomy and bilateral salpingo-oophorectomy) work in reducing the risk of ovarian cancer for women with BRCA1 mutations. Bilateral salpingectomy involves the surgical removal of fallopian tubes, and bilateral salpingo-oophorectomy involves the surgical removal of both the fallopian tubes and ovaries. This study may help doctors determine if the two surgical procedures are nearly the same for ovarian cancer risk reduction for women with BRCA1 mutations.